Budesonide Suppository Composition for Room-Temperature Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing rectal pharmaceutical formulations for treating inflammatory diseases like Crohn's disease and ulcerative colitis, such as enemas and suppositories, suffer from instability at room temperature, patient discomfort, and inadequate local application, particularly those containing budesonide, which degrades quickly due to oxidation.
Innovation Solution
A storage-stable budesonide suppository formulation using a specific solid fat base with a narrow melting and freezing point, micronized budesonide, ascorbyl palmitate as an antioxidant, and a gas-tight packaging to maintain stability and ease of use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If budesonide is formulated in rectal preparations for treating inflammatory bowel diseases, then therapeutic efficacy is improved, but storage stability deteriorates due to oxidation at room temperature
Solution Approach 1:
The patent employs an inert atmosphere by incorporating antioxidants (ascorbic acid, tocopherol) and using nitrogen-flushed packaging to prevent oxidation of budesonide during storage. This creates a protective environment that maintains pharmacological activity while allowing room temperature storage for extended periods.
Solution Approach 2:
The formulation uses a composite approach by combining budesonide with multiple excipients including solid fats (witepsol H15, Witepsol W45), antioxidants, and surfactants. This composite formulation enhances stability while maintaining therapeutic efficacy, resolving the contradiction between reliability and compositional stability.
2Quantity of substance
If suppository size is increased to provide adequate dosage, then therapeutic effect is improved, but patient comfort deteriorates due to painful insertion
Solution Approach 1:
The patent optimizes the physical parameters of the suppository by carefully selecting solid fat bases with specific melting points (33-36°C) and adjusting the hardness through combinations of witepsol H15 and Witepsol W45. This creates a formulation that is soft enough for comfortable insertion yet maintains structural integrity for adequate dosing.
3Ease of operation
If melting point of solid fat base is decreased for easier insertion, then ease of operation is improved, but storage stability deteriorates
Solution Approach 1:
The patent uses a composite solid fat system combining witepsol H15 (melting point 33-35°C) and witepsol W45 (melting point 35-36°C) in specific ratios. This composite approach achieves an optimal balance where the formulation remains stable during storage yet becomes sufficiently soft at body temperature for comfortable insertion.
Solution Approach 2:
The formulation carefully controls the melting point parameter of the solid fat base to fall within the narrow range of 33-36°C. This parameter optimization ensures the suppository maintains structural stability at room temperature while becoming pliable at body temperature, resolving the contradiction between storage stability and insertion ease.
4Speed
If budesonide is dissolved in the preparation for rapid release, then speed of action is improved, but storage stability deteriorates due to increased oxidation risk
Solution Approach 1:
The patent employs antioxidants (ascorbic acid at 0.03-0.06% and tocopherol at 0.02-0.05%) to create a protective chemical environment that prevents oxidation of dissolved budesonide during storage. This allows the drug to remain in dissolved form for rapid release while maintaining storage stability through the inerting effect of the antioxidants.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation maintains at least 90% pharmacological activity of budesonide for 24 months at room temperature, ensures painless insertion, and provides effective local application without mucosal irritation, enhancing patient compliance and therapeutic efficacy.
Implementation Method 1
budesonide is decomposed to biologically inactive or less active decomposition products... addition of ascorbyl palmitate as an antioxidant
Implementation Method 2
solid fat with a narrow melting and freezing point... after insertion is used for the treatment of inflammatory diseases of the rectum
Data Source
AI summary
Disclosed is a storage-stable pharmaceutical formulation for rectal administration, containing budesonide or a pharmaceutically compatible salt or derivative thereof, and at least 80 wt % of a solid fat or a mixture of different solid fats, based on the total weight of the formulation, as well as at least one anti-oxidation agent that is compatible therewith.